NCT00006099View on ClinicalTrials.gov

Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 2, 2000

Primary Completion Date

February 26, 2002

Study Completion Date

August 12, 2002

Conditions
Ovarian Cancer
Interventions
BIOLOGICAL

Monoclonal antibody hu3S193

Hu3S193 was to be administered intraperitoneally or intravenously at a dose of 5mg. Doses of hu3S193 were radiolabeled with 5 mCi of 111In.

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Ludwig Institute for Cancer Research

OTHER